Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer
Cells · 2024
DOI: 10.3390/cells13181569 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cells, 2024. Verfasst von Linus Winter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Cranio-Maxillofacial Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Skin Neoplasms, CD28 Antigens, B7-H1 Antigen, B7-2 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Friedrich-Alexander University Erlangen-Nuremberg "ELAN-Anschubfinanzierung", Friedrich-Alexander University Erlangen-Nuremberg “ELAN-Anschubfinanzierung”.
Abstract (Originalsprache)
The establishment of immunotherapy applying immune checkpoint inhibitors (ICI) has provided an important new option for the treatment of solid malignant diseases. However, different tumor entities show dramatically different responses to this therapy. BCC responds worse to anti-PD-1 ICIs as compared to cSCC. Differential immune checkpoint expression could explain this discrepancy and, therefore, the aim of this study was to analyze activating and inhibitory immune checkpoints in cSCC and BCC tissues. Tissue microarrays of the invasive front as well as the tumor core of BCC and cSCC samples were used to evaluate PD-1, PD-L1, CD28, and CD86 expression and their topographic distribution profiles by chromogenic immunohistochemistry. QuPath was used to determine the labeling index. The expression of PD-1, PD-L1, and CD28 was significantly higher in both the tumor core and the invasive front of cSCC samples as compared to BCC (p < 0.001). In addition, the ratios of PD-L1/CD86 (p < 0.001) and CD28/CD86 (p < 0.001) were significantly higher in cSCC. The invasive front of both tumor entities showed higher expression levels of all immune markers compared to the tumor core in both tumor entities. The significantly higher expression of PD-1, PD-L1, and CD28 in cSCC, along with the predominance of the inhibitory ligand PD-L1 as compared to the activating CD86 in cSCC, provide a potential explanation for the better objective response rates to anti-PD-1 immunotherapy as compared to BCC. Furthermore, the predominant site of interaction between the immune system and the tumor was within the invasive front in both tumor types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Cranio-Maxillofacial Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
- Comprehensive Cancer Center Alliance WERA (CCC WERA), 91052 Erlangen, Germany.
- Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany.
- Department of Operative Dentistry and Periodontology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
ORCID-Profile: Jutta Ries, Rainer Lutz, Marco Kesting, Manuel Weber
Förderung
- Friedrich-Alexander University Erlangen-Nuremberg "ELAN-Anschubfinanzierung"
- Friedrich-Alexander University Erlangen-Nuremberg “ELAN-Anschubfinanzierung”
Zitieren
APA
Winter, L., Ries, J., Vogl, C., Trumet, L., Geppert, C. I., Lutz, R., Kesting, M., & Weber, M. (2024). Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer. Cells. https://doi.org/10.3390/cells13181569
Vancouver
Winter L, Ries J, Vogl C, Trumet L, Geppert CI, Lutz R, et al. Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer. Cells. 2024. doi:10.3390/cells13181569
BibTeX
@article{Winter2024,
author = {Winter, Linus and Ries, Jutta and Vogl, Christoph and Trumet, Leah and Geppert, Carol Immanuel and Lutz, Rainer and Kesting, Marco and Weber, Manuel},
title = {Comparative Analysis of Inhibitory and Activating Immune Checkpoints PD-1, PD-L1, CD28, and CD86 in Non-Melanoma Skin Cancer},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13181569}
}
EUVIMED